112 related articles for article (PubMed ID: 26181263)
1. Cabozantinib-Getting Under the Skin of Cutaneous Toxicity.
Jayaram A; Zafeiriou Z; de Bono JS
JAMA Oncol; 2015 Jul; 1(4):535-6. PubMed ID: 26181263
[No Abstract] [Full Text] [Related]
2. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.
Zuo RC; Apolo AB; DiGiovanna JJ; Parnes HL; Keen CM; Nanda S; Dahut WL; Cowen EW
JAMA Dermatol; 2015 Feb; 151(2):170-7. PubMed ID: 25427282
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous leucocytoclastic vasculitis secondary to cabozantinib therapy for renal cell carcinoma.
Coltart GS; Sutton JE; Roche HJ; Sommerlad MP; Crabb SJ; Healy E
Clin Exp Dermatol; 2021 Jun; 46(4):739-740. PubMed ID: 33332666
[No Abstract] [Full Text] [Related]
4. [Acute Myocardial Infarction and Purpuric Drug Eruption Caused by Erlotinib Combined with Cabozantinib:Report of One Case].
Li T; Jia LJ; Zhang J; Hu Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Apr; 41(2):278-282. PubMed ID: 31060687
[TBL] [Abstract][Full Text] [Related]
5. Skin eruption and cholestatic hepatic injury due to vismodegib.
Drago F; Trave I; Wei Y; Parodi A
G Ital Dermatol Venereol; 2019 Aug; 154(4):496-497. PubMed ID: 29199802
[No Abstract] [Full Text] [Related]
6. Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.
Hirotsu KE; Rana J; Wang JY; Raghavan SS; Rieger KE; Srinivas S; Fan AC; Kwong BY; Novoa RA; Zaba LC
J Am Acad Dermatol; 2021 Dec; 85(6):1610-1611. PubMed ID: 33301805
[No Abstract] [Full Text] [Related]
7. 9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient.
Kieny A; Kremer V; Scheidecker S; Lipsker D
Acta Derm Venereol; 2018 Feb; 98(2):287-288. PubMed ID: 29057423
[No Abstract] [Full Text] [Related]
8. Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib.
Franck N; Barete S; Moguelet P; Blanchet B; Carlotti A; Ropert S; Avril MF; Francès C; Billemont B; Goldwasser F
J Clin Oncol; 2010 Nov; 28(31):e640-2. PubMed ID: 20855839
[No Abstract] [Full Text] [Related]
9. Radiation Recall Dermatitis Consecutive to Cabozantinib Use.
Kumar V; Meghal T; Wu E; Huang Y
Am J Ther; 2019; 26(4):e559-e561. PubMed ID: 28816724
[No Abstract] [Full Text] [Related]
10. Treatment of Cabozantinib-Related Palmar-Plantar Erythrodysesthesia With Topical Sildenafil, Diclofenac, and Gabapentin Cream: A Case Report.
Thai KJ; Ralph C; England D
JCO Oncol Pract; 2020 Mar; 16(3):135-136. PubMed ID: 31721626
[No Abstract] [Full Text] [Related]
11. Non-pigmenting fixed drug eruption induced by sorafenib.
Tanabe K; Amoh Y; Mii S; Eto H; Iwamura M; Katsuoka K
Acta Derm Venereol; 2010 May; 90(3):307. PubMed ID: 20526556
[No Abstract] [Full Text] [Related]
12. Cabozantinib-induced hand-foot skin reaction with subungual splinter hemorrhages and hypertension: a possible association with inhibition of the vascular endothelial growth factor signaling pathway.
Cho YT; Chan CC
Eur J Dermatol; 2013 Apr; 23(2):274-5. PubMed ID: 23518371
[No Abstract] [Full Text] [Related]
13. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
14. Visual vignette. Cabozantinib-induced hand-foot syndrome.
Esfandiari NH; Hesseltine EA
Endocr Pract; 2013; 19(6):1071. PubMed ID: 24014004
[No Abstract] [Full Text] [Related]
15. Reversible cutaneous side effects of vismodegib treatment.
Kwong B; Danial C; Liu A; Chun KA; Chang AL
Cutis; 2017 Mar; 99(3):E19-E20. PubMed ID: 28398426
[No Abstract] [Full Text] [Related]
16. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.
Belum VR; Serna-Tamayo C; Wu S; Lacouture ME
Clin Exp Dermatol; 2016 Jan; 41(1):8-15. PubMed ID: 26009777
[TBL] [Abstract][Full Text] [Related]
17. The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells.
Shintani T; Kusuhara Y; Daizumoto K; Dondoo TO; Yamamoto H; Mori H; Fukawa T; Nakatsuji H; Fukumori T; Takahashi M; Kanayama H
Urology; 2017 Mar; 101():169.e7-169.e13. PubMed ID: 28013036
[TBL] [Abstract][Full Text] [Related]
18. Effective and Tolerable Treatment of Advanced Basal Cell Carcinoma With Vismodegib Despite Renal Insufficiency.
Maul LV; Kähler KC; Hauschild A
JAMA Dermatol; 2016 Dec; 152(12):1387-1388. PubMed ID: 26720040
[No Abstract] [Full Text] [Related]
19. [Palmoplantar cutaneous reaction to sorafenib].
Echeverría B; Llombart B; Botella-Estrada R; Guillén C
Actas Dermosifiliogr; 2009 Oct; 100(8):736-7. PubMed ID: 19775561
[No Abstract] [Full Text] [Related]
20. Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis.
Zhang X; Shao Y; Wang K
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1109-15. PubMed ID: 27181268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
